06 Oct Official launch of OHMX.bio, partner for high-throughput OMICS solutions
Ghent, 29 September 2019. Novalis is proud to release OHMX.bio, the fifth instalment in its portfolio of biotechnology and life sciences related companies. OHMX.bio is a Ghent based company that provides a complete R&D platform helping customers resolve their biological questions through cutting-edge technologies in different -omics fields: (epi)genomics, transcriptomics, translatomics and proteomics.
As a spin-off initiative of the Ghent University, OHMX.bio can profit from a deep academic expertise. OHMX.bio is working in the interaction field between bioinformatics and life sciences, making it a logical addition to the Novalis portfolio. Current flagships in its portfolio are ribosome profiling and third generation sequencing.
With its in-house developed high performant ribosome profiling service, OHMX.bio provides a genome-wide assessment of mRNA targeted by translating ribosomes. This highly sensitive sequencing-based technology unravels the translatome, a snapshot of RNA that is being translated. Quantification of gene-specific translation, discovery of non-canonical translation events, investigation of ribosome elongation speed and pausing, figuring out translation regulation by microRNAs and RNA-binding proteins and/or determination of mechanisms related to translation initiation and termination, are made possible.
OHMX.bio also services third generation sequencing workflows based on the Oxford Nanopore Technology. Direct DNA and RNA solutions allow for amplification-free sequencing of (ultra-)long reads and additionally allow to map their epigenetic features. Applications are everywhere, in the fields of clinical and more specifically cancer research, environmental and plant research, microbiology and microbiome analysis, genome and transcriptome research.